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Design of ExperimentsAbstract A simple, rapid, sensitive, robust, stability-indicating RP-HPLC-PDA analytical
protocol was developed and validated for the analysis of zileuton racemate in bulk and in tablet
formulation. Development of method and resolution of degradation products from forced; hydro-
lytic (acidic, basic, neutral), oxidative, photolytic (acidic, basic, neutral, solid state) and thermal
(dry heat) degradation was achieved on a LC – GC Qualisil BDS C18 column
(250 mm · 4.6 mm · 5 lm) by isocratic mode at ambient temperature, employing a mobile phase
methanol and (0.2%, v/v) orthophosphoric acid in ratio of (80:20, v/v) at a ﬂow rate of
1.0 mL min1 and detection at 260 nm. ‘Design of Experiments’ (DOE) employing ‘Central
Composite Design’ (CCD) and ‘Response Surface Methodology’ (RSM) were applied as an
advancement to traditional ‘One Variable at Time’ (OVAT) approach to evaluate the effects of
variations in selected factors (methanol content, ﬂow rate, concentration of orthophosphoric acid)
as graphical interpretation for robustness and statistical interpretation was achieved with Multiple
Linear Regression (MLR) and ANOVA. The method succeeded over the validation parameters:esearch,
iffmail.
bai, MS
Figure 1 Chemical struc
274 S.B. Ganorkar et al.linearity, precision, accuracy, limit of detection and limit of quantitation, and robustness. The
method was applied effectively for analysis of in-house zileuton tablets.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Zileuton [R,S (±) N-(1-(benzo [b]-thien-2-yl) ethyl)-N-
hydroxyurea] (Fig. 1) is a racemic mixture having approxi-
mately equal therapeutic activities (Erdman, 1992) which selec-
tively and reversibly inhibits 5-lypoxygenase potentiating
leukotrienes (LT’s – LTA4, LTB4, LTC4, LTD4 and LTE4
(Rask-Madson et al., 1992); mostly indicated in inﬂammatory
diseases akin to psoriasis, rheumatoid arthritis, asthma, multi-
ple sclerosis, uveitis and inﬂammatory bowel syndrome. Zileu-
ton is a very slightly soluble compound without any ionizable
functional group (Qui et al., 1997). Recently, the molecule has
been reported in the literature as a new efﬁcient and safe anti-
acne drug (Zouboulis, 2009) and employed in USA to treat
asthma. The ofﬁcial monograph in the United States Pharma-
copeia (United States Pharmacopeia 34-NF 29, 2011); men-
tioned assay of zileuton via RP-HPLC-UV with application
of a mobile phase containing buffers, mentioned ﬂow rate
(1.5 mL min1 and 2.2 mL min1 for RS) and stationary phase
(Spherisorb ODS1 chromatographic column, 10 lm). The
objective of the present study is directed towards development
of stability – indicating method which could offer some advan-
tages with respect to speed of analysis, simplicity in determina-
tion along with simultaneous resolution of drug and impurities
generated during stress studies (Snyder et al., 1997). Literature
depicts very critical, rare and atypical reports for efﬁcient ana-
lytical determination of zileuton viz. . . Preparative separation
and analysis of the enantiomers of [14C] zileuton (Thomas
and Surber, 1992), kinetics and mechanism of chemical degra-
dation in aqueous solutions by HPLC (Alvarez and Slade,
1992), HPLC determination with its N-dehydroxylated metab-
olite in plasma (Granneman et al., 1995), simultaneous deter-
mination along with N-dehydroxylated metabolite in
untreated rat urine using HPLC (Thomas and Albazi, 1996),
electrochemical reduction behaviour of zileuton at a dropping
mercury electrode by polarography (Shreedhar et al., 2010)
and one report on solubility and stability characterization of
zileuton in a ternary solvent system assisted with HPLC
(Trivedi et al., 1996).
Recently, authors successfully developed, simple ‘Zero
order UV-spectrophotometric’ and ‘First order derivative
UV-spectrophotometric’, methods for determination of zileu-
ton (Ganorkar et al., 2013a) and a novel high-performance
thin-layer chromatography (HPTLC) and UV-spectroscopic
area under curve (UV-AUC) methods for determination ofture for zileuton.zileuton racemate for efﬁcient routine analysis of drug in bulk
and pharmaceutical formulations (Ganorkar et al., 2013b).
Determination of robustness during analytical method val-
idation is gaining immense signiﬁcance with respect to; statis-
tical quality control monitoring, study of the factors that
negatively affects the quality in pharmaceutical analysis, pro-
cesses such as transfer of analytical method protocol from
donor site to acceptor site, strict regulations demanded by reg-
ulatory authorities and as per recent suggestions by FDA; the
use of ‘Quality by Design’ (QBD) or ‘Design of Experiments’
(DOE) strategy is recommended to achieve these goals (Wal-
ter, 2011). ‘One Variable at a Time’ (OVAT) approach and
‘Design of Experiments’ (DOE) are two different possible
ways; used to assess robustness (Dejaegher and Heyden,
2007) amongst these; DOE is usually employed to study the
simultaneous variations of factors for a response (Murthy
et al., 2013).
Literature revealed some design methodologies to assess
robustness of method such as; full factorial design, fractional
factorial designs, Asymmetrical Factorial Designs (AFD),
Central Composite Design (CCD) either as Circumscribed or
Face-centred (Dejaegher and Heyden, 2007), Doehlert
Designs, Box–Behnken Design (BBD), Plackett–Burman
Design (PBD), Star Designs (Goupy, 2005); assisted with
graphical methods of interpretation such as Normal probabil-
ity plot, half-normal probability plot, bar plot with or without
limit value, counter plot, standardized pareto chart and
response surface method (RSM) (Dejaegher and Heyden,
2007). If the method of analysis is fast and requires testing
of few factors (three or less) a good choice for robustness test-
ing may be CCD which is widely employed because of its high
efﬁciency with respect to the number of runs required (Pet-
kovska et al., 2008). RSM was applied to investigate behaviour
of the response around optimized values of the factors (Ficarra
et al., 2002) which allows studying complete interaction of
effects produced due to all variables at a time and demon-
strates the experimental region around centre of interest
(Shrinubabu et al., 2007).
Hence, in continuation to our quest for developing simple,
rapid, economical and effective methods for the analysis of
zileuton racemate; authors of this manuscript hereby wish to
put forth a reliable, sensitive stability-indicating RP-HPLC-
PDA analysis of zileuton racemate; assisted with DOE and
CCD for evaluation of robustness of developed method fol-
lowed by graphical interpretation of data by RSM and statis-
tical interpretation by ANOVA and MLR.
2. Experimental
2.1. Drugs and reagents
Zileuton standard was obtained as a gift sample from Bio-
phore India Ltd. (Hyderabad, India), (85% w/v) orthophos-
phoric Acid (OPA), Hydrogen peroxide (30% w/v), Sodium
RP-HPLC-PDA analysis of zileuton formulation 275starch glycolate (SSG) and Micro-crystalline Cellulose (MCC)
were procured from Loba Chemie, India. Methanol (HPLC
Grade), sodium hydroxide (NaOH) and hydrochloric Acid
(HCl), were purchased from Merck Ltd., India. Double dis-
tilled water was used throughout the analysis.
2.2. Equipments and experimental conditions
Analysis was performed on UFLC – LC 20 AD (Shimadzu
Corporation, Japan) consisting of LC – 20 AD binary sol-
vent delivery system (pump), SPD-M20A diode array detec-
tor and CTO – 10 AS vp; column oven, a rheodyne injector
with 20 ll loop and a Hamilton syringe (100 ll). Separations
were achieved on a LC – GC Qualisil BDS C18 column
(250 mm · 4.6 mm, 5 lm). Data collection and analysis were
performed with LC-solution (Shimadzu Corporation, Japan).
Stress degradation studies were assisted with i-Therm
AI-7981, thermostatic Water Bath with digital controller.
All weighing operations for the present analysis were carried
out with the help of SHIMADZU AUX-120 analytical
balance. Ultrasonication of samples was performed using
Ultrasonicator; ENERTECH Electronics Pvt. Ltd., India.
2.3. Preparation of in-house zileuton tablets
As the tablet formulation was not available in Indian market;
tablets containing 600 mg of zileuton were prepared in-house
using direct compression technique and employing SSG as
super disintegrant and MCC as diluent. Prepared tablets were
used as pharmaceutical formulation for further analysis.
2.4. Preparation of stock standard solution and study of
calibration curve
Stock solution of zileuton was prepared with a concentration
of 100 lg mL1 in a mixture of methanol and (0.2% v/v)
OPA (80:20 v/v). Determination of linearity involved analysis
of six working solutions having concentrations 2 lg mL1,
4 lg mL1, 6 lg mL1, 8 lg mL1, 10 lg mL1 and
12 lg mL1, respectively; obtained by serial dilution of stock
standard solution with mobile-phase. Resulted peak areasTable 1 Optimized stress conditions for zileuton and generated deg
Stress
conditions
Stressor & its
concentration
Exposure
condition
Hydrolysis
Acidic 0.5 N HCl 60 C
Basic 0.1 N NaOH 60 C
Neutral Distilled Water 80 C
Oxidation 3% H2O2 RT
Photolysisb
Acidic 0.01 N HCl Sunlight
Basic 0.01 N NaOH Sunlight
Neutral Distilled water Sunlight
Solid state – Sunlight
Thermalc – 100 C
b Exposure of samples to direct sunlight during all conditions of photo
c Sample spread as thin layer exposed to dry heat in hot air oven.and concentrations were subjected to regression analysis to
establish a relationship as calibration curve.
2.5. Preparation of sample solution
The sample solution was prepared from in-house formulated
zileuton tablets. The quantity of pulverized tablet mass equiv-
alent to 50 mg zileuton was transferred into 100 mL volumetric
ﬂask containing 25 mL of methanol, after ultrasonication for
20 min; volume was made up to the mark to get the concentra-
tion of 500 lg mL1. The resulting solution was ﬁltered
through a 0.45 lm ﬁlter (Milliﬁlter, Milford, MA, USA). From
ﬁltrate, appropriate volumes of solution were transferred using
micropipettes into 10 mL volumetric ﬂasks and the volume
was made up to the mark with mobile phase to obtain the ﬁnal
concentrations of 8 lg mL1. Resulting solutions were sub-
jected to proposed method for further analysis.
2.6. Chromatographic conditions
HPLC system: UFLC– LC 20 AD (Shimadzu Corporation,
Japan)
Detector: SPD– M 20 A (Diode array detector)
Column: LC– GC Qualisil BDS C18
Dimensions: (250 mm · 4.6 mm, 5 lm)
Mobile-phase: methanol: (0.2% v/v) OPA, (80:20 v/v)
Mode: Isocratic
Flow rate: 1.0 mL min1
Temperature: Ambient temperature
Detection wavelength: 260 nm
Injection volume: 20 lLr
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sis.2.7. Stress degradation studies for zileuton
The optimized LC method was used to study the degradation
behaviour of the drug under various stress conditions. Stress
studies were carried out as per ICH Q1A (R2) recommenda-
tions for hydrolysis, oxidation, thermal (dry heat stress) andcorresponding retention time.
Degradants and respective retention
time (tR) (min)
III (2.78), VII (5.15), IX (6.79)
II (2.54), III (2.78), IV (3.15), VII (5.15)
II (2.54), III (2.78), IV (3.15), VII (5.15)
I (2.42), IV (3.15), VI (4.87)
IV (3.15), VI (4.87), XII (7.42)
V (3.6), VII (5.15), VIII (5.80), XI (7.31)
VI (4.87), XIII (7.52)
I (2.42), III (2.78), VI (4.87)
I (2.42), III (2.78), VII (5.15), X (7.15)
276 S.B. Ganorkar et al.Q1B recommendations for photolysis. The stressors, choice of
its concentration and preparation of samples were based on
pre-developed laboratory protocol. The optimized stressed
conditions are enlisted in Table 1.
As the drug was insoluble in water; hydrolytic stress was
induced by dissolving 10 mg of drug in methanolic solution
of stressor in a 10 mL volumetric ﬂask and volume was made
up to the mark. Resulting solution was transferred into a
50 mL round bottom ﬂask (RBF); ﬁtted with a reﬂux con-
denser and reﬂuxed for speciﬁed period. Sample solution
(0.1 mL) was withdrawn with a 1.0 mL pipette and neutralized.
Volume of resulting solution was made up to 10 mL using
mobile phase; in a 10 mL volumetric ﬂask. Solution thus
obtained was then subjected to chromatographic determina-
tion. Sample solutions from all stressed situations were diluted
with mobile phase to achieve a ﬁnal concentration of
10 lg mL1 before injecting into HPLC system.
2.7.1. Acidic hydrolysis
Acidic hydrolytic stress was induced by dissolving an accu-
rately weighed quantity of drug equal to 10 mg in 0.5 M meth-
anolic HCl and resulting solution was reﬂuxed at 60 C for
12 h in a thermostatic water bath. Sample solution (0.1 mL)
was withdrawn and subjected to neutralization using dilute
methanolic NaOH solution and subjected to chromatographic
analysis.
2.7.2. Basic hydrolysis
For alkaline hydrolysis; 10 mg of zileuton was weighed accu-
rately as described before and dissolved in 0.1 M methanolic
NaOH; reﬂuxed at 60 C for 4 h. Sample solution (0.1 mL)
was withdrawn and neutralized with dilute methanolic HCl.
Solution thus obtained was then subjected to chromatographic
determination.
2.7.3. Neutral hydrolysis
To study the effect of hydrolysis in neutral environment 10 mg
of drug was dissolved in a mixture of methanol and double dis-
tilled water (2:8 v/v) as described previously and reﬂuxed at
80 C for 12 h. Appropriate quantity of stress induced sample
was withdrawn; diluted and resulting solution was subjected to
analysis by the developed chromatographic method.
2.7.4. Oxidative degradation
Oxidative stress was induced to sample by dissolving 10 mg of
drug in hydrogen peroxide (3% v/v) and volume was made up
to the mark in a 10 mL volumetric ﬂask. Resulting solution
was kept in dark at room temperature for 6 h to avoid any deg-
radation by combination of exposed light and oxidative stres-
sor. An appropriate volume of stressed sample was withdrawn;
diluted and introduced to optimized chromatographic
conditions.
2.7.5. Photo degradation
Photolysis was carried out by exposing samples directly to sun-
light in acidic (0.01 M HCl), basic (0.01 M NaOH) and neutral
(distilled water) medium. Photolytic stress in solid state was
induced by spreading sample as a thin layer; which was kept
for 12 h for two days in all four cases. The samples were with-
drawn; acidic and basic samples were neutralized; diluted andsubjected to analysis by the developed chromatographic
method.
2.7.6. Thermal (dry heat degradation)
Thermal stress study was conducted by placing approximate
quantity of drug equal to 100 mg in a sealed ampoule and
keeping it in a digital thermostatic block at 100 C for 8 h.
From stressed sample 10 mg of drug was weighed and dis-
solved in mobile phase and diluted up to the mark in 10 mL
volumetric ﬂask. Resulting solution was diluted as stated
before and subjected to analysis.
3. Method validation
The optimized method was validated as to ensure it for linear-
ity, precision, LOD, LOQ and robustness as per recommenda-
tions of International Conference on Harmonisation (ICH)
guidelines (International Conference on Harmonisation,
2005).
3.1. Accuracy
Accuracy of the method was evaluated by spiking the drug
standard in predetermined tablet solution at concentration lev-
els of 80%, 100% and 120% and determined as percent recov-
ery studies.
3.2. Precision
The precision for an analytical method illustrates information
on the random errors. It represents the closeness of agreement
between a series of measurements obtained from multiple sam-
pling of the same homogenous sample under optimized condi-
tions. It is divided into repeatability (intra-day precision),
intermediate precision (inter-day precision).
Intra-day and inter-day precisions for present RP-HPLC-
PDA analysis were determined by analysing, three different
concentrations 4 lg mL1, 6 lg mL1 and 8 lg mL1 using
three repetitive measurements at each target concentration
level.
3.3. Limit of detection (LOD) and limit of quantitation (LOQ)
The determination of LOD and LOQ was based on the aver-
age standard deviations of the responses and slopes of con-
structed calibration curves (n= 3) as described by ICH
guidelines Q2 (R1). Hence sensitivity of the proposed method
was estimated in terms of LOD and LOQ using formulae;
LOD= 3.3 · ASD/S and LOQ= 10 · ASD/S; where, ‘ASD’
is the average standard deviation and ‘S’ is the slope of corre-
sponding calibration curve. LOD and LOQ were estimated at
lower range of calibration curve in between 2 lg mL1 and
4 lg mL1 at concentrations of 2 lg mL1, 2.5 lg mL1,
3.0 lg mL1, 3.5 lg mL1, and 4.0 lg mL1.
3.4. Robustness and experimental design methodology for
robustness
Method robustness was evaluated as per ICH to determine the
constancy of the results when variables inherent to the method
RP-HPLC-PDA analysis of zileuton formulation 277of analysis are varied deliberately and it depicts the reliability of
the analytical procedure opted. Robustness testing was per-
formed in order to obtain information about those critical
parameters affecting the response (peak area, retention time
and found concentration). To study the simultaneous variations
of the factors on the considered responses, a multivariate
approachDOEwithCCDwas applied. Simultaneous variations
of the factors can be studied effectively using DOE approach
which was applied efﬁciently to test method robustness. CCD
was employed to obtain predictive model describing the changes
in the responses within the experimental domain.
A CCD in ‘k’ factors require ‘2k’ factorial runs, ‘2k’ axial
experiments, symmetrically spaced at ±a along each variable
axis and at least one centre point. Two or ﬁve Central repeti-
tions are generally carried out in order to know the experimen-
tal error variance and to test the predictive validity of the
model (Lunsted et al., 1998). Statistical validation of polyno-
mial equations generated by Design Expert software (version
8.0.1, Stat-Ease Inc., Minneapolis, MN) was established by
analysis of variance (ANOVA) and coefﬁcients of second order
quadratic model were estimated by least square regression.
Multiple linear regression statistical models result in predictor
equations incorporating interactive and polynomial terms for
evaluation of mutual relationships between the input varia-
tions and output responses; quoted as second order polyno-
mial with the form:
y ¼ b0 þ b1x1 þ b2x2 þ b3x3 þ b12x1x2 þ b13x1x3
þ b23x2x3 þ b11x21 þ b22x22 þ b33x23 ð1Þ
where, ‘y’ is the measured response (dependent variable) asso-
ciated with the each factor level combination; ‘b0’ represents
the polynomial equation intercept representing average arith-
metic mean of all quantitative outcomes of eighteen runs and
‘b1–b33’ are regression coefﬁcients computed from the observed
experimental values of ‘y’. ‘x1’, ‘x2’ and ‘x3’ represent the
coded levels of independent variables where x1: content of
methanol (% v/v), x2: ﬂow rate (mL min
1) and x3: concentra-
tion of OPA (% v/v); ranges selected for independent variablesTable 2 Generated experimental domain for robustness testing and
Run Methanol
(% v/v) (x1)
Flow rate
(mL min1) (x2)
Conc. of OPA
(% v/v) (x3)
1 75 0.9 0.1
2 75 1.1 0.3
3 85 1.1 0.3
4 80 1 0.2
5 85 1 0.2
6 75 1.1 0.1
7 75 1 0.2
8 85 0.9 0.3
9 80 1 0.3
10 80 1 0.1
11 80 1.1 0.2
12 85 1.1 0.1
13 80 1 0.2
14 85 0.9 0.1
15 80 0.9 0.2
16 80 1 0.2
17 80 1 0.2
18 75 0.9 0.3during determination of method robustness were; (75–85),
(0.9–1.1) and (0.1–0.3), respectively for x1, x2, and x3. The
optimized values obtained for x1, x2, and x3 were 80% v/v,
1.0 mL min1 and 0.2% v/v, respectively. The x1x2, x1x3 and
x2x3 represent the interaction terms. Polynomial terms x
2
1, x
2
2
and x23 are included to investigate the type of model. The con-
sidered responses were peak area (y1), retention time (min) (y2)
and found concentration (%) (y3). The experimental domain
of the selected variables is reported as represented in Table 2.
Three dimensional surface responses were plotted to easily
and more precisely deﬁne the effect of variations on method
robustness which allowed predicting the behaviour of analyte
slightly outside the experimental domain.
3.5. System suitability study
According to the United States Pharmacopeia, system suitabil-
ity tests are integral part of liquid chromatographic methods.
Retention time, capacity factor, number of theoretical plates,
and asymmetry factor were calculated for standard solutions.
The values for retention time (tR), capacity factor (k
0), theoret-
ical plates (N) and asymmetry factor obtained from system
suitability study were found to be 4.201 min, 1.356, 5431.475
and 0.334, respectively. The data was found to be within
acceptable limit.
4. Results and discussion
4.1. Optimization of chromatographic conditions
Different mobile phases were tested with a view to achieve sim-
ple, rapid and economical separation between drug and degra-
dation products. The optimal mobile phase composition was
found to be methanol (0.2% v/v) and orthophosphoric acid
(80:20 v/v) and the run time was 10 min. Before analysis, both
the mobile phase and sample solutions were ﬁltered through a
0.45 lmmembrane ﬁlter and degassed for 15 min in ultrasonica-
tor. Chromatographic studies were performed at ambient tem-obtained responses.
Peak area
(y1)
Retention time
(min) (y2)
Found conc. (%) (y3)
455860 5.257 111.927
385007 3.64 94.44
369031 3.534 90.5
408121 4.199 100.146
411533 3.887 100.988
375242 4.33 92.0327
409320 4.71 100.44
452976 4.32 111.2153
410924 4.228 100.838
410457 4.256 100.7228
371488 3.844 91.10633
377748 3.56 92.6511
407734 4.196 100.05
451555 4.317 110.8646
452676 4.667 111.1413
408362 4.197 100.2058
408281 4.199 100.1858
449800 5.218 110.4316
Table 3 Results from precision studies for RP-HPLC-PDA
analysis of zileuton.
Drug Zileuton
Concentration
(lg mL1)
Amount found
in lg mL1
[n= 9] ± SD
RSD (%)
Intra-day precision
4 4.002 ± 0.009 0.23
6 6.005 ± 0.012 0.21
8 7.977 ± 0.022 0.27
Inter-day precision
4 3.997 ± 0.017 0.42
6 6.000 ± 0.014 0.23
8 7.955 ± 0.036 0.46
278 S.B. Ganorkar et al.perature. The optimized ﬂow rate was 1.0 mL min1 with an
injection volume 20 ll followed by detection at wavelength of
260 nm.
4.2. Linearity study
Determination of linearity and establishment of calibration
curve involved plotting graph between peak areas obtained
versus concentrations. Linear relationship was obtained for
the concentration range of 2–12 lg mL1 with a slope ± SD
of 50,654 ± 183.22, intercept ± SD of 2296 ± 45.88 and
correlation coefﬁcient ± SD of 0.999 ± 0.0001. The regres-
sion equation obtained during determination of linearity
was, y= 50,654 x+ 2296.
4.3. Method validation
4.3.1. Accuracy
Accuracy of the developed method was evaluated in terms of
percent recovery studies at three different levels 80%, 100%
and 120%; percentage of drug recovered, when known amount
of standard drug was added to pre-analysed samples and sub-Table 4 The estimates of CCD regression analysis and statistical p
Statistical parameters y1: Area
R2 a 0.9925
R2 adj. 0.9841
SDb 3752.5
C.V.%c 3752.5
DFd 9
SSe 14949836154.738
MSf 1661092906.0821
F-ratiog 117.964849
p-value <0.0001
a Coefﬁcient of regression.
b Standard deviation.
c Coefﬁcient of variations.
d Degrees of freedom.
e Sum of squares.
f Mean sum of squares.
g Fischer’s ratio.jected to proposed HPLC method was 99.84% (% RSD 0.34),
101.21% (% RSD 0.88) and 99.79% (% RSD 0.87), respec-
tively with mean percent recovery of 100.28%. The determina-
tion involved measurement in triplicate at each level with
relative standard deviation in range of 0.34% to 0.87% with
a mean percentage RSD of 0.70.
4.3.2. Precision
Intra-day and inter-day precisions were perceived using six
repetitive measurements in target concentration level. The pre-
cision of developed method was evaluated in terms of % RSD.
For intra-day and inter-day precision % RSD values were
found to be in range of 0.23–0.27 and 0.42–0.46, respectively.
Results for the intra-day and inter-day precision studies are
represented in Table 3.
4.3.3. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
The determination of LOD and LOQ was based on the
standard deviations of the responses and slopes of constructed
calibration curves (n= 3) as described by ICH guidelines Q2
(R1). The LOD and LOQ values found were 0.22 lg and
0.78 lg, respectively.
4.3.4. Robustness and design analysis for robustness
Three factor face centred design (FCD) consisting of eighteen
experiments including four replicates at each centre point was
used. All experiments were performed in randomized order to
minimize the effects of uncontrolled factors that may introduce
biased responses. Rather than analysis of single coefﬁcient
whole model equation was used and for response surface
analysis; crucial focus was given to factors whose responses
are with or without signiﬁcance and are considered too.
Equations obtained from the model were with the forms:
y1 ¼ 1216972 5743:39x1  768191x2 þ 78179:93x3
 3085:25x1x2  2750:25x1x3 þ 71087:5x2x3
þ 57:06x21 þ 308221:40x22 þ 169071:40x23 ð2Þarameters of ANOVA for robustness studies of zileuton.
y2: Retention time y3: Conc. of OPA
0.9782 0.9925
0.9537 0.9841
0.1046 0.9258
2.4594 0.9157
9 9
3.9335274801587 910.43549734121
0.43705860890653 101.15949970458
39.94223812197 118.02000249801
<0.0001 <0.0001
Figure 2 3D response surface plots for Area – peak area (y1), RT – retention time (y2) and FC – found concentration (y3); against ﬂow
rate vs. methanol content – (A), (D), (G); ﬂow rate versus concentration of OPA (B), (E), (H) and concentration of OPA versus methanol
content – (C), (F), (I).
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þ 0:2405x1x2 þ 0:1765x1x3  8:5x2x3 þ 0:002072x21
þ 0:879762x22  0:47024x23 ð3Þy3 ¼ 299:6321 1:41265x1  189:705x2 þ 19:25577x3
 0:76072x1x2  0:67807x1x3 þ 17:51125x2x3
þ 0:01405x21 þ 76:10569x22 þ 41:76419x23 ð4Þ
Table 5 Summary of regression, validation and in-house
tablet formulation assay parameters for stability indicating RP-
HPLC-PDA analysis of zileuton.
Parameters RP-HPLC-PDA
Regression parameters results
Regression coeﬃcient 0.999 ± 0.001
Slope ± SD 50,654 ± 183.22
Intercept ± SD 2296 ± 45.88
Concentration range [lg mL1] 2–12
Validation parameters
Intra-day precision, n= 9 (RSD, %) 0.23–0.27
Inter-day precision, n= 9 (RSD, %) 0.42–0.46
Accuracy, n= 6 (mean recovery, %± SD) 100.28%± 0.70
LOD (lg) 0.22
LOQ (lg) 0.78
Robustness Robust
Tablet assay
Drug content (%± SD) 99.94%± 0.54
Figure 3 (A–J) Chromatograms, showing zileuton and its degradatio
degradants in different stress conditions).
280 S.B. Ganorkar et al.Estimation of experimental error and measurement of
validity of polynomial models (lack of ﬁt) were obtained
through repetition of experimental points (optimized level of
variables). ANOVA was used to obtain regression lack of ﬁt.
As the calculated F-ratios were not greater than the tabled
F-values at 95% conﬁdence level there was no evidence of
models lack of ﬁt and the models were provided with adequate
representation of data. Taking into account the degrees of free-
dom it was indicated that the data is well ﬁtted to regression
models as depicted in Table 4 (Ferreira et al., 2007).
As per the values of coefﬁcients from the polynomial mod-
els and their signs (Eqs. (2)–(4)), x1 (methanol content) and x2
(ﬂow rate) have negative inﬂuence on the responses; y1 (peak
area), y2 (retention time) and y3 (found concentration) while
x3 (concentration of OPA) has the positive effect on y1 and
y3 and negative effect on y2. Response surfaces from DOE
revealed linear models (suggested) for all the three variables
(x1, x2 and x3) and depicted least inﬂuences of the methanol
content and concentration of OPA while ﬂow rate showed
the highest inﬂuence on area, retention time and found concen-
tration; respectively. When concentration of OPA was kept
constant; the increase in the content of methanol in mobile
phase and ﬂow rate leads to decrease in the peak area and
retention time and increased found concentration of the ana-n products in various stress conditions applied (I–XIII are zileuton
RP-HPLC-PDA analysis of zileuton formulation 281lyte. Steepness of the response surface plots (Fig. 2A–I) dem-
onstrates that when one of the factors was held constant at a
speciﬁed level, usually the proposed optimum; deliberate
change in the ﬂow rate; affected peak area (y1) more as com-
pared to other two factors (Fig. 2A and B). On the other side
keeping ﬂow rate constant (Fig. 2C, F, I) resulted in no consid-
erable change in peak area and found concentration while
retention time deviated slightly even though the methanol con-
tent and concentration of OPA varied notably; decrease in
ﬂow rate increased area and vice versa. Increase in the ﬂow
rate resulted in decreased found concentration and retention
time (Fig. 2D, E, G, H), while the methanol content and
OPA had no prevailing effect over the ﬂow rate of mobile
phase.
4.3.5. Assay of in-house zileuton tablet formulation
Assay of in-house zileuton tablets containing 600 mg of zileu-
ton along with SSG and MCC was performed at a concentra-
tion of 8 lg mL1. Percent drug content for zileuton in-house
tablets was found to be 99.94%± 0.54.
Summary of regression, validation and in-house tablet for-
mulation assay parameters for stability indicating RP-HPLC-
PDA analysis of zileuton is represented in Table 5.
4.4. Stress degradation studies
Degradation products with their respective retention time (tR)
and optimized stress conditions are represented in Table 1.
Chromatogram for zileuton standard (Fig. 3A) depicted a sin-
gle major peak at 4.0 min. Acidic hydrolysis resulted in three
degradation products represented as III, VII and IX
(Fig. 3B), four degradation products II, III, IV, and VII; were
produced during basic hydrolysis (Fig. 3C), neutral hydrolysis
showed four degradation products II, III, IV, and VII
(Fig. 3D). Oxidative stress in 3% H2O2 (Fig. 3E), formed three
degradation products I, IV, and VI while photolysis on expo-
sure of drug in acidic medium produced degradants IV, VI and
XII (Fig. 3F), in alkaline medium V, VII, VIII and XI
(Fig. 3G), in neutral medium (Fig. 3H) only VI and XIII
and in solid state stress (Fig. 3I) resulted in degradants I, III
and VI. Exposure to dry heat (Fig. 3J) produced four degra-
dants I, III, VII and X.5. Conclusions
A simple and rapid stability-indicating RP-HPLC-PDA
method was developed and validated successfully for the
analysis of zileuton in bulk and in in-house tablet formula-
tion. DOE and CCD were employed effectively for evalua-
tion of robustness and statistical analysis showed that the
model represents the phenomenon quite well and the varia-
tions in responses were correctly co-related to the variations
of the factors. From results of ANOVA and analysis of
response surfaces plots; it can be concluded that responses,
y1, peak area; y2, retention time and y3, found concentra-
tion; are robust for x1 and x3 within selected range but
for x2, ﬂow rate; a precautionary statement should be
included in the analytical procedure. The main advantages
of the method over the USP method are the use of simplest
mobile phase, optimum ﬂow rate, low system pressure, andlower column length with simultaneous resolution of degra-
dation products in isocratic mode. Stress studies revealed
that drug was most susceptible to acidic and basic hydroly-
sis; susceptibility towards oxidative stress was lesser and
least for photolytic and thermal (dry heat) stress and
resulted in a total of thirteen degradation products (I– XIII).
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